EMA Application withdrawn: Canakinumab Novartis (Canakinumab) — Novartis Europharm Limited

View source ↗

Summary

The EMA has withdrawn the application for canakinumab by Novartis Europharm Limited for indications in acute coronary syndrome, myocardial infarction, and strok…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Stroke

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Status: Application withdrawn. Therapeutic area: Acute Coronary Syndrome;Myocardial Infarction;Stroke. MAH: Novartis Europharm Limited